
PHARMATHER HOLDINGS LTD.
CONDENSED INTERIM CONSOLIDATED FINANCIAL
STATEMENTS
THREE AND SIX MONTHS ENDED NOVEMBER 30,
2024 AND 2023
(EXPRESSED IN CANADIAN DOLLARS)
(UNAUDITED)

Notice To Reader

The accompanying unaudited condensed interim consolidated financial statements of PharmaTher Holdings Ltd. (the "Company") have been prepared by and are the responsibility of management. The unaudited condensed interim consolidated financial statements have not been reviewed by the Company's auditors.

PharmaTher Holdings Ltd.

Condensed Interim Consolidated Statements of Financial Position

(Expressed in Canadian Dollars)

(Unaudited)

	As at November 30, 2024	As at May 31, 2024
ASSETS		
Current assets		
Cash	\$ 1,486,546	\$ 2,133,231
Amounts receivable	23,579	23,478
Prepaid expense	82	15,148
Investment (note 3)	66,667	166,667
Total current assets	1,576,874	2,338,524
Non-current assets		
Investment in associate (note 4)	235,084	251,270
Total assets	\$ 1,811,958	\$ 2,589,794
LIABILITIES AND EQUITY		
Current liabilities		
Accounts payable and accrued liabilities (note 10(a))	\$ 220,799	\$ 250,855
Due to related party (note 10(a)(vi))	2,102	2,046
Total liabilities	222,901	252,901
Equity		
Share capital (note 5)	8,504,977	8,504,977
Warrants and broker warrants (note 6)	4,113,811	4,113,811
Contributed surplus (note 7)	546,046	546,046
Deficit	(11,575,777)	(10,827,941)
Total equity	1,589,057	2,336,893
Total liabilities and equity	\$ 1,811,958	\$ 2,589,794

The accompanying notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.

Business of the Company and going concern (note 1)

Commitments (note 11)

On Behalf of the Board:

"Fabio Chianelli"
Director

"Carlo Sansalone"
Director

PharmaTher Holdings Ltd.**Condensed Interim Consolidated Statements of Loss and Comprehensive Loss****(Expressed in Canadian Dollars)****(Unaudited)**

	Three months ended November 30,		Six months ended November 30,	
	2024	2023	2024	2023
Expenses				
Research (notes 10 and 12)	\$ 94,547	\$ 681,017	\$ 177,780	\$ 1,747,754
Professional fees (note 10)	29,110	28,170	76,496	64,007
Consulting fees (note 10(a)(i))	125,457	109,117	245,457	278,297
General and administrative (note 10)	75,904	79,514	146,847	153,550
Shareholder information and filing fees	21,275	17,612	28,850	25,516
Comprehensive loss before below items	(346,293)	(915,430)	(675,430)	(2,269,124)
Unrealized loss on investment (note 3)	(33,333)	(180,000)	(100,000)	(193,333)
Interest income	18,835	50,571	43,780	118,871
Loss from investment in associate (note 4)	(6,883)	(14,018)	(16,186)	(48,393)
Net loss and comprehensive loss for the period	\$ (367,674)	\$ (1,058,877)	\$ (747,836)	\$ (2,391,979)
Basic and diluted net loss for the period (note 9)	\$ (0.00)	\$ (0.01)	\$ (0.01)	\$ (0.03)
Weighted average number of common shares outstanding - basic and diluted	88,519,065	88,169,065	88,519,065	88,169,065

The accompanying notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.

PharmaTher Holdings Ltd.**Condensed Interim Consolidated Statements of Changes in Equity****(Expressed in Canadian Dollars)****(Unaudited)**

	Share Capital		Warrants and broker warrants	Contributed Surplus	Deficit	Total
	Number of shares	Amount				
Balance, May 31, 2023	88,169,065	\$ 8,442,315	\$ 4,113,811	\$ 645,999	\$ (7,784,892)	\$ 5,417,233
Net loss for the period	-	-	-	-	(2,391,979)	(2,391,979)
Balance, November 30, 2023	88,169,065	\$ 8,442,315	\$ 4,113,811	\$ 645,999	\$ (10,176,871)	\$ 3,025,254
Balance, May 31, 2024	88,519,065	\$ 8,504,977	\$ 4,113,811	\$ 546,046	\$ (10,827,941)	\$ 2,336,893
Net loss for the period	-	-	-	-	(747,836)	(747,836)
Balance, November 30, 2024	88,519,065	\$ 8,504,977	\$ 4,113,811	\$ 546,046	\$ (11,575,777)	\$ 1,589,057

The accompanying notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.

PharmaTher Holdings Ltd.**Condensed Interim Consolidated Statements of Cash Flows****(Expressed in Canadian Dollars)****(Unaudited)**

Six months ended November 30,	2024	2023
Operating activities		
Net loss for the period	\$ (747,836)	\$ (2,391,979)
Adjustments for:		
Depreciation	-	711
Loss from investment in associate (note 4)	16,186	48,393
Unrealized loss on investment (note 3)	100,000	193,333
Non-cash working capital items:		
Amounts receivable	(101)	28,404
Prepaid expenses	15,066	-
Accounts payable and accrued liabilities	(30,056)	(345,968)
Due to related party	56	(684)
Net cash (used in) operating activities	(646,685)	(2,467,790)
Investing activities		
Investment in associate	-	(300,000)
Net cash (used in) investing activities	-	(300,000)
Net change in cash	(646,685)	(2,767,790)
Cash, beginning of period	2,133,231	5,919,808
Cash, end of period	\$ 1,486,546	\$ 3,152,018

The accompanying notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.

PharmaTher Holdings Ltd.

Notes to Condensed Interim Consolidated Financial Statements

November 30, 2024

(Expressed in Canadian Dollars)

(Unaudited)

1. Business of the Company and going concern

PharmaTher Holdings Inc. ("PharmaTher" or the "Company") was incorporated under the Business Corporations Act (British Columbia). The registered head office of the Company is 82 Richmond Street East, Toronto, Ontario M5C 1P1.

PharmaTher is a specialty pharmaceutical company focused on the development and commercialization of KETARX™ (Ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications.

On July 18, 2023, PharmaTher acquired 49% interest in Sairyo Therapeutics Inc., which focuses on advancing the clinical development of an improved and patented enteric-coated orally bioavailable formulation of cepharranthine (PD-001) to treat responsive cancers and infectious diseases, including COVID-19.

On October 1, 2020, the Company's common shares were approved for listing on the Canadian Securities Exchange (the "CSE") and began trading on the CSE under the trading symbol "PHRM" as of market open on October 9, 2020.

On January 13, 2021, the common shares of the Company were approved for trading on the OTCQB® Venture Market ("OTCQB"). The Company's U.S. listing will trade under the symbol "PHRRF" while the Company's primary Canadian listing will continue to trade on the Canadian Securities Exchange under "PHRM".

These unaudited condensed interim consolidated financial statements were prepared on a going concern basis of presentation, which assumes that the Company will continue operations for the foreseeable future and be able to realize the carrying value of its assets and discharge its liabilities and commitments in the normal course of business. To date, the Company has not earned significant revenue and incurred a comprehensive loss of \$747,836 during the six months ended November 30, 2024.

The Company's ability to continue as a going concern is dependent upon raising additional capital to meet its present and future commitments. If additional financing is arranged through the issuance of shares, control of the Company may change and shareholders may suffer significant dilution. In addition, the Company has not generated any revenue to date. These circumstances indicate that material uncertainties exist that may cast significant doubt about the Company's ability to continue as a going concern and, accordingly, the ultimate use of accounting principles applicable to a going concern. The consolidated financial statements do not reflect adjustments to the carrying values and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern, and such adjustments may be material.

PharmaTher Holdings Ltd.

Notes to Condensed Interim Consolidated Financial Statements

November 30, 2024

(Expressed in Canadian Dollars)

(Unaudited)

2. Basis of Presentation and Material Accounting Policies

Statement of compliance

The Company applies International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). These unaudited condensed interim consolidated financial statements have been prepared in accordance with International Accounting Standard 34, Interim Financial Reporting. Accordingly, they do not include all of the information required for full audited annual financial statements.

The policies applied in these unaudited condensed interim consolidated financial statements are based on IFRS issued and outstanding as of January 21, 2025, the date the Board of Directors approved the statements. The same accounting policies and methods of computation are followed in these unaudited condensed interim consolidated financial statements as compared with the most recent financial statements as at and for the year ended May 31, 2024, except as noted below. Any subsequent changes to IFRS that are given effect in the Company's annual consolidated financial statements for the year ending May 31, 2025 could result in restatement of these unaudited condensed interim consolidated financial statements.

Accounting pronouncements not yet adopted

IFRS 18, Presentation and Disclosure in Financial Statements

IFRS 18 will replace IAS 1, Presentation of Financial Statements aims to improve how companies communicate in their financial statements, with a focus on information about financial performance in the statement of profit or loss, in particular additional defined subtotals, disclosures about management-defined performance measures and new principles for aggregation and disaggregation of information. IFRS 18 is accompanied by limited amendments to the requirements in IAS 7, Statement of Cash Flows. IFRS 18 is effective from January 1, 2027. Companies are permitted to apply IFRS 18 before that date.

3. Investment

During the year ended May 31, 2021, the Company received 6,666,667 shares of Revive Therapeutics Ltd. ("Revive") valued at \$4,000,000 and cash of \$3,000,000 for sale of the full rights to PharmaTher's intellectual property pertaining to psilocybin. As at November 30, 2024, the fair value of investment in Revive shares was \$66,667 (May 31, 2024 - \$166,667), resulting in an unrealized loss on investment of \$33,333 and \$100,000, respectively, during the three and six months ended November 30, 2024 (three and six months ended November 30, 2023 - loss of \$180,000 and \$193,333, respectively).

4. Investment in associate

On July 18, 2023, PharmaTher Inc. the wholly-owned subsidiary of PharmaTher Holdings Ltd, entered into a unanimous shareholders agreement pursuant to which PharmaTher Inc. will subscribe for 72,058,824 common shares of PharmaDrug Inc. ("PharmaDrug")'s subsidiary Sairiyo Therapeutics Inc. ("Sairiyo") for \$300,000. PharmaTher Inc. became a 49% shareholder of Sairiyo. In the event that PharmaDrug elects not to participate in any new issuance of Sairiyo shares, PharmaTher Inc. may increase its ownership from 49% to 51% with an investment of \$250,000. Either side may increase its ownership by 10% for additional \$100,000 investments. Neither side may be diluted beyond a 10% carried interest.

The Company is diversifying its research portfolio with its stake in Sairiyo, whose sole asset is a patented reformulated version of the drug Cepharranthine as a potential treatment for medical countermeasures and cancer. Based on the terms of the unanimous shareholders agreement, management has assessed that the Company has significant influence over Sairiyo and that the investment should be accounted for using the equity method of accounting.

PharmaTher Holdings Ltd.

Notes to Condensed Interim Consolidated Financial Statements

November 30, 2024

(Expressed in Canadian Dollars)

(Unaudited)

4. Investment in associate (continued)

A continuity of the Company's investment in associate is as follows:

	Carrying value of investment in associate
Balance, May 31, 2023	\$ -
Initial investment	300,000
Share of loss	(48,393)
Balance, November 30, 2023	251,607
Share of loss	(337)
Balance, May 31, 2024	251,270
Share of loss	(16,186)
Balance, November 30, 2024	\$ 235,084

Summarized financial information of Sairyo based on the financial statements of Sairyo is set out below:

As at November 30, 2024

Cash	\$ 35,720
Total current assets	\$ 35,720
Total non-current assets	\$ 577,847
Total current liabilities	\$ (977,079)
Net loss	\$ (33,033)
Proportinate share of loss	\$ (16,186)

5. Share capital

a) Authorized share capital

Authorized unlimited common shares and unlimited number of preferred shares

b) Common shares issued

	Number of Common Shares	Amount (\$)
Balance, May 31, 2023 and November 30, 2023	88,169,065	8,442,315
Exercise of stock options	350,000	35,000
Reclassification of fair value of stock options exercised	-	27,662
Balance, May 31, 2024 and November 30, 2024	88,519,065	8,504,977

PharmaTher Holdings Ltd.

Notes to Condensed Interim Consolidated Financial Statements

November 30, 2024

(Expressed in Canadian Dollars)

(Unaudited)

6. Warrants and broker warrants

The Company issued warrants and broker warrants to acquire common shares as follows:

	Number of Warrants	Weighted Average Exercise Price (\$)
Balance, May 31, 2023, November 30, 2023, May 31, 2024 and November 30, 2024	16,875,000	0.80

The following table reflects the warrants and broker warrants issued and outstanding as of November 30, 2024:

Expiry Date	Exercise Price (\$)	Weighted Average Remaining Contractual Life (years)	Number of Warrants Outstanding
September 28, 2026	0.80	1.83	15,625,000
September 28, 2026	0.80	1.83	1,250,000
	0.80	1.83	16,875,000

7. Stock options

The Company issued stock options to acquire common shares as follows:

	Number of Stock Options	Weighted Average Exercise Price (\$)
Balance, May 31, 2023 and November 30, 2023	5,699,000	0.16
Expired	(750,000)	0.18
Exercised	(350,000)	0.10
Balance, May 31, 2024 and November 30, 2024	4,599,000	0.16

The following table reflects the actual stock options issued and outstanding as of November 30, 2024:

Expiry Date	Exercise Price (\$)	Weighted Average Remaining Contractual Life (years)	Number of Options Outstanding	Number of Options Vested (Exercisable)
July 16, 2025	0.10	0.62	3,099,000	3,099,000
September 10, 2026	0.91	1.78	250,000	250,000
March 30, 2027	0.18	2.33	250,000	250,000
April 4, 2027	0.16	2.34	500,000	500,000
April 18, 2027	0.15	2.38	500,000	500,000
	0.16	1.16	4,599,000	4,599,000

PharmaTher Holdings Ltd.

Notes to Condensed Interim Consolidated Financial Statements

November 30, 2024

(Expressed in Canadian Dollars)

(Unaudited)

8. Capital management

The Company considers its capital to be its shareholders' equity. As at November 30, 2024, the Company had shareholders' equity of \$1,589,057. The Company's objective when managing its capital is to seek continuous improvement in the return to its shareholders while maintaining a moderate to high tolerance for risk. The objective is achieved by prudently managing the capital generated through internal growth and profitability, through the use of lower cost capital, including raising share capital or debt when required to fund opportunities as they arise. The Company may also return capital to shareholders through the repurchase of shares, pay dividends or reduce debt where it determines any of these to be an effective method of achieving the above objective. The Company does not use ratios in the management of its capital. There have been no changes to management's approach to managing its capital during the period ended November 30, 2024.

9. Net loss per share

The calculation of basic loss per share for the three and six months ended November 30, 2024 was based on the loss attributable to common shareholders of \$367,674 and \$747,836, respectively (three and six months ended November 30, 2023 - loss of \$1,058,877 and \$2,391,979, respectively) and the basic weighted average number of common shares outstanding of 88,519,065 (three and six months ended November 30, 2023 - 88,169,065). Diluted loss per share for the three and six months ended November 30, 2024 did not include the effect of 16,875,000 warrants and broker warrants (three and six months ended November 30, 2023 - 16,875,000) and 4,599,000 options (three and six months ended November 30, 2023 - 5,699,000) as they are anti-dilutive.

10. Related party transactions

(a) Related party balances and transactions

Related parties include the directors of the Company, close family members and enterprises which are controlled by these individuals as well as persons performing similar functions.

	Three months ended November 30,		Six months ended November 30,	
	2024	2023	2024	2023
Fabiotech Inc. (i)	\$ 90,000	\$ 90,000	\$ 180,000	\$ 180,000
Marrelli Support Services Inc. ("MSSI") (ii)	\$ 13,703	\$ 16,934	\$ 27,239	\$ 27,174
DSA Corporate Services Inc. ("DSA") (iii)	\$ 10,390	\$ 8,412	\$ 15,415	\$ 16,411
Larnic Inc. (iv)	\$ 45,000	\$ 45,000	\$ 90,000	\$ 90,000
Marrelli Trust Company Limited ("Marrelli Trust") (v)	\$ 2,466	\$ 2,577	\$ 3,768	\$ 3,642

(i) Fees are related to services of Fabio Chianelli to act as the Chief Executive Officer ("CEO") of the Company. Fabio Chianelli is the owner of Fabiotech Inc. As at November 30, 2024, \$nil (May 31, 2024 - \$nil) was owed to the CEO.

(ii) Fees are related to services of Carmelo Marrelli to act as the Chief Financial Officer ("CFO") of the Company. Carmelo Marrelli is the Managing Director of MSSI. Services were incurred for bookkeeping, accounting and CFO services. As at November 30, 2024, MSSI was owed \$2,544 (May 31, 2024 - \$2,318) and this amount was included in accounts payable and accrued liabilities. This amount is unsecured and non-interest bearing.

(iii) The CFO of the Company is an officer of DSA and the Corporate Secretary of the Company is an employee of DSA. Fees are related to corporate secretarial and filing services provided by DSA. As at November 30, 2024, DSA was owed \$4,803 (May 31, 2024 - \$3,955) and this amount was included in accounts payable and accrued liabilities. This amount is unsecured and non-interest bearing.

PharmaTher Holdings Ltd.

Notes to Condensed Interim Consolidated Financial Statements

November 30, 2024

(Expressed in Canadian Dollars)

(Unaudited)

10. Related party transactions (continued)

(a) Related party balances and transactions (continued)

(iv) During the three and six months ended November 30, 2024, the Company incurred consulting fees of \$45,000 and \$90,000, respectively (three and six months ended November 30, 2023 - \$45,000 and \$90,000, respectively) to a company controlled by the spouse of the CEO and the consulting fees have been included in research expenses, which services supported aspects of the product and clinical development, regulatory and market research of the Company's product pipeline. As at November 30, 2024, the company controlled by the spouse of the CEO was owed \$nil (May 31, 2024 - \$nil).

(v) The CFO of the Company is a director of Marrelli Trust. Marrelli Trust provided stock transfer services to the Company. As at November 30, 2024, Marrelli Trust was owed \$1,860 (May 31, 2024 - \$463) and this amount was included in accounts payable and accrued liabilities. This amount is unsecured and non-interest bearing.

(vi) During the year ended May 31, 2021, one of the officers of the Company paid research and development expenses in the amount of \$2,608 on behalf of the Company. As at November 30, 2024, the Company owed \$2,102 (May 31, 2024 - \$2,046) to the officer.

(b) Remuneration of directors and key management

In accordance with IAS 24, key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company directly or indirectly, including any directors (executive and non-executive) of the Company. During the three and six months ended November 30, 2024 and 2023, the Company incurred no remuneration of management with the exception of the consulting fees paid to the CEO and CFO as outlined above.

(c) Major shareholders

To the knowledge of the directors and senior officers of the Company, as at November 30, 2024, no person or corporation beneficially owns or exercises control over common shares of the Company carrying more than 10% of the voting rights attached to all common shares of the Company other than Mr. Fabio Chianelli who owns 17.53% of the Company. The holding can change at any time at the discretion of the owners.

None of the Company's major shareholders have different voting rights compared to holders of the Company's common shares.

The Company is not aware of any arrangements the operation of which may at a subsequent date result in a change in control of the Company. To the knowledge of the Company, it is not directly or indirectly owned or controlled by another corporation, by any government or by any natural or legal person severally or jointly.

PharmaTher Holdings Ltd.

Notes to Condensed Interim Consolidated Financial Statements

November 30, 2024

(Expressed in Canadian Dollars)

(Unaudited)

11. Commitments

The Company has entered into an exclusive patent license agreement with the Arizona Board of Regents on behalf of the University of Arizona, whereby certain milestone payments and royalties are payable upon the achievement of certain events. The Company will record these amounts as the events occur.

The Company has entered into an exclusive license agreement with The University of Kansas, whereby certain milestone payments and royalties are payable upon the achievement of certain events. The Company will record these amounts as the events occur.

12. Research

Ketamine

PharmaTher has entered into an exclusive license agreement with the University of Arizona for the development and commercialization of ketamine in the treatment of Parkinson's disease and the Company is developing a novel injectable and intravenous ketamine product. During the three and six months ended November 30, 2024, the Company incurred \$66,974 and \$132,864, respectively (three and six months ended November 30, 2023 - \$572,710 and \$1,564,397, respectively) in the research of Ketamine for the treatment of Parkinson's disease and its novel injectable and intravenous ketamine product.

Microneedle

PharmaTher entered into an exclusive worldwide patent and know-how license agreement with The Queen's University of Belfast to develop and commercialize a patented hydrogel-forming microneedle patch delivery technology. During the three and six months ended November 30, 2024, the Company incurred \$22,500 and \$45,000, respectively (three and six months ended November 30, 2023 - \$40,290 and \$70,290, respectively) in the research of Microneedle patch.

Other

During the three and six months ended November 30, 2024, the Company incurred \$5,073 and (\$84), respectively (three and six months ended November 30, 2023 - \$68,017 and \$113,067, respectively) on expenses related to research including research advisory, drug repurposing, pre-clinical and regulatory expenditures.

13. Contingent asset

During the year ended May 31, 2023, the Company signed a settlement agreement with Relevium Technologies Inc. ("Relevium") relating to a lawsuit commenced by the Company against Relevium for breach of contract regarding a take-over transaction. Per the agreement, Relevium is to issue shares to the Company for a value of \$225,000 once Relevium's Cease Trade Order with TSX Venture Exchange is lifted.